ASBIS INVESTS IN A BIOTECHNOLOGY COMPANY FROM THE SECTOR OF ADVANCED DERMACEUTICALS FOR ONCOLOGICAL PATIENTS

ASBIS INVESTS IN A BIOTECHNOLOGY COMPANY FROM THE SECTOR OF ADVANCED DERMACEUTICALS FOR ONCOLOGICAL PATIENTS

PRESS RELEASE - 22 November 2022; Limassol, Cyprus, and Warsaw, Poland

ASBISc Enterprises Plc (WSE: ASB), a leading Value-Added Distributor, developer and supplier of IT and IoT products, solutions and services in the growing markets of Europe, Middle East and Africa, invested EUR 700 thousand in the biotechnology company RSL Revolutionary Labs Ltd., which offers unique products for the treatment and regeneration of the skin for cancer patients, developed in cooperation with scientists, dermatologists and oncology specialists.

The funds will be used for clinical trials on new products based on innovative collagen preparations and to increase production capacity, thanks to which it will be possible not only to meet the needs of the local market, but also the international expansion of the Company.

As announced, ASBIS continues to diversify its activities by investing in another company from the biotechnology sector, operating in a growing market and at an early stage of development.

RSL Revolutionary Labs is a Cypriot biotechnology company founded in 2019, offering a line of innovative products specifically targeted at treating specific skin diseases of cancer patients. They use novel molecularly engineered medical grade biomaterials. The products do not contain harmful chemicals and preservatives.

In 2020, 19.3 million cases of cancer were recorded, and it is estimated that the global cancer burden will amount to as much as 28.4 million cases in 2040, an increase of 47% compared to 2020. Patients undergoing oncological treatment are struggling with serious dermatological problems. The available skin care options for cancer patients are still quite limited, and products designed specifically for patients suffering from dermatological side effects are still not widely available, are usually not effective, and may contain potentially harmful chemicals. 

Serhei Kostevitch, CEO of ASBIS Group,commented: “ASBIS has innovation in its DNA. We also have resources to help develop companies that can bring real value to our lives and improve its quality. That is why we are investing in another company from the biotechnology sector that develops proprietary, advanced products using the latest research on the use of collagen among others. The solutions that RSL Revolutionary Labs is working on can bring relief to millions of people around the world struggling with skin effects caused by cancer.

Dr. Marianna Prokopi-Demetriades, Co-founder and CEO of RSL Revolutionary Labs,commented:“We are extremely proud to have acquired an investor such as ASBIS. The ASBIS investment will enable us to significantly expand our current production and marketing capacities to support global expansion. Thanks to the funds received, we will also develop a new line of innovative advanced products validated through multi-centered clinical trials. ASBIS also gives us access to the most modern laboratories located in the new ASBIS High Technology Cluster Hub in Limassol, which greatly facilitates our research work.”

About ASBISc Enterprises Plc 

ASBIS Group is a leading Value Add Distributor, developer and provider of IT, IoT products, solutions and services to the markets of Europe, the Middle East and Africa (EMEA) with local operations in Central and Eastern Europe, the Baltic republics, the former Soviet Union, the Middle East and North Africa. 

The business of ASBIS is based on three pillars:
1. Distribution of hardware and software for Client Computing and Data Centers, consumer electronics thru:
    a.   Retail chains and e-tailers
    b.   Resellers to small and medium business
    c.   Large enterprises.
2. Full stack in creation of world class products. From scientific research and development to design and engineering, firmware and software, production and marketing of IT and IoT products and solutions via own brands:
    a.      Aeno (small home appliances).
    b.     Canyon (smart watches, power banks, accessories for computers and mobile devices)
    c.     Perenio (IoT platform, IoT routers, applications and peripherals for smart office/ home, smart health).
    d.     Prestigio (smart devices and accessories, innovative solutions for business and education, etc.)
    e.     Lorgar (accessories for gaming and streaming)
3.     Complex solutions sales projects to large enterprises via extensive networks of System Integrators and Value Add Resellers. 

ASBIS was founded in 1990, since 1995 operates from Cyprus. Company has two master distribution centers located in the Czech Republic and in the United Arab Emirates, subsidiaries in 27 countries, more than 2,200 employees and about, 20 000 active customers in 56 countries worldwide. In 2021, the Group delivered sales of close to USD 3.1 billion. 

The Company’s stock has been listed on the Warsaw Stock Exchange since October 2007 under the ticker symbol “ASB” (ASBIS). 

For more news and information visit: www.asbis.com 

About RSL Revolutionary Labs Ltd

RSL Revolutionary Labs, founded in 2019, is a biotech company, offering unique skincare formulations designed in collaboration with scientists, dermatologists and oncology specialists and validated through vigorous R&D and clinical data, to address emergent needs in oncology patients. RSL provides unique natural products with the addition of novel molecularly engineered medical grade biomaterials specially formulated to alleviate skin irritation and promote wound and burn healing in cancer-associated skin conditions. 

For more news and information visit: www.rsl-labs.com

Disclaimer: The information contained in each press release posted on this site was factually accurate on the date it was issued. While these press releases and other materials remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases and other materials should not rely upon the information as current or accurate after their issuance dates.